Differing effects of PTH 1-34, PTH 1-84, and zoledronic acid on bone microarchitecture and estimated strength in postmenopausal women with osteoporosis: An 18-month open-labeled observational study using HR-pQCT

Journal of Bone and Mineral Research

Volumn 28, Issue 4, 2013, Pages 736-745

  Hansen, Stinus ^a,b   Hauge, Ellen M ^c   Beck Jensen, Jens Erik ^d   Brixen, Kim ^a,b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d HVIDOVRE HOSPITAL   (Denmark)

Author keywords

anti osteoporotic treatment; HR PQCT; osteoporosis; PTH 1 34; PTH 1 84; zoledronic acid

Indexed keywords

PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; ZOLEDRONIC ACID; BIOLOGICAL MARKER; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE STRENGTH; BONE STRUCTURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORTICAL BONE; CORTICAL THICKNESS (BONE); DRUG DOSE REDUCTION; DRUG EFFECT; FEMALE; FINITE ELEMENT ANALYSIS; HIGH RESOLUTION PERIPHERAL QUANTITATIVE COMPUTED TOMOGRAPHY; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; POROSITY; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; RADIUS; STATISTICAL SIGNIFICANCE; TIBIA; TRABECULAR BONE; BIOMECHANICS; BONE; BONE REMODELING; DRUG EFFECTS; METABOLISM; MIDDLE AGED; OSTEOPOROSIS; PATHOLOGY; PATHOPHYSIOLOGY; PHOTON ABSORPTIOMETRY; RADIOGRAPHY; TIME FACTOR; VERY ELDERLY;

ABSORPTIOMETRY, PHOTON; AGED; AGED, 80 AND OVER; BIOMARKERS; BIOMECHANICAL PHENOMENA; BONE AND BONES; BONE REMODELING; DIPHOSPHONATES; FEMALE; FINITE ELEMENT ANALYSIS; HUMANS; IMIDAZOLES; MIDDLE AGED; OSTEOPOROSIS; PARATHYROID HORMONE; POSTMENOPAUSE; RADIUS; TIBIA; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84875302132     PISSN: 08840431     EISSN: 15234681     Source Type: Journal    
DOI: 10.1002/jbmr.1784     Document Type: Article

References (41)

1. Lindsay R, Cosman F, Zhou H, Bostrom MP, Shen VW, Cruz JD, Nieves JW, Dempster DW., A novel tetracycline labeling schedule for longitudinal evaluation of the short-term effects of anabolic therapy with a single iliac crest bone biopsy: early actions of teriparatide. J Bone Miner Res. 2006 Mar; 21 (3): 366-73.
2. Ma YL, Zeng Q, Donley DW, Ste-Marie LG, Gallagher JC, Dalsky GP, Marcus R, Eriksen EF., Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res. 2006 Jun; 21 (6): 855-64.
3. Greenspan SL, Bone HG, Ettinger MP, Hanley DA, Lindsay R, Zanchetta JR, Blosch CM, Mathisen AL, Morris SA, Marriott TB., Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med. 2007 Mar 6; 146 (5): 326-39.
4. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH., Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001 May 10; 344 (19): 1434-41.
5. Reeve J, Meunier PJ, Parsons JA, Bernat M, Bijvoet OL, Courpron P, Edouard C, Klenerman L, Neer RM, Renier JC, Slovik D, Vismans FJ, Potts JT Jr., Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. Br Med J. 1980 Jun 7; 280 (6228): 1340-4.
6. Dempster DW, Cosman F, Parisien M, Shen V, Lindsay R., Anabolic actions of parathyroid hormone on bone. Endocr Rev. 1993 Dec; 14 (6): 690-709.
7. Burr DB, Hirano T, Turner CH, Hotchkiss C, Brommage R, Hock JM., Intermittently administered human parathyroid hormone(1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J Bone Miner Res. 2001 Jan; 16 (1): 157-65.
8. Fox J, Miller MA, Newman MK, Recker RR, Turner CH, Smith SY., Effects of daily treatment with parathyroid hormone 1-84. for 16 months on density, architecture and biomechanical properties of cortical bone in adult ovariectomized rhesus monkeys. Bone. 2007 Sep; 41 (3): 321-30.
9. Boutroy S, Bouxsein ML, Munoz F, Delmas PD., In vivo assessment of trabecular bone microarchitecture by high-resolution peripheral quantitative computed tomography. J Clin Endocrinol Metab. 2005 Dec; 90 (12): 6508-15.
10. Pistoia W, Van Rietbergen B, Lochmuller EM, Lill CA, Eckstein F, Ruegsegger P., Image-based micro-finite-element modeling for improved distal radius strength diagnosis: moving from bench to bedside. J Clin Densitom. 2004; 7 (2): 153-60.
11. Macdonald HM, Nishiyama KK, Hanley DA, Boyd SK., Changes in trabecular and cortical bone microarchitecture at peripheral sites associated with 18 months of teriparatide therapy in postmenopausal women with osteoporosis. Osteoporos Int. 2011 Jan; 22 (1): 357-62.
12. Graeff C, Chevalier Y, Charlebois M, Varga P, Pahr D, Nickelsen TN, Morlock MM, Gluer CC, Zysset PK., Improvements in vertebral body strength under teriparatide treatment assessed in vivo by finite element analysis: results from the EUROFORS study. J Bone Miner Res. 2009 Oct; 24 (10): 1672-80.
13. Bauer DC, Garnero P, Bilezikian JP, Greenspan SL, Ensrud KE, Rosen CJ, Palermo L, Black DM., Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2006 Apr; 91 (4): 1370-5.
14. Pauchard Y, Liphardt AM, Macdonald HM, Hanley DA, Boyd SK., Quality control for bone quality parameters affected by subject motion in high-resolution peripheral quantitative computed tomography. Bone. 2012 Jun; 50 (6): 1304-10.
15. Buie HR, Campbell GM, Klinck RJ, MacNeil JA, Boyd SK., Automatic segmentation of cortical and trabecular compartments based on a dual threshold technique for in vivo micro-CT bone analysis. Bone. 2007 Oct; 41 (4): 505-15.
16. Burghardt AJ, Buie HR, Laib A, Majumdar S, Boyd SK., Reproducibility of direct quantitative measures of cortical bone microarchitecture of the distal radius and tibia by HR-pQCT. Bone. 2010 Sep; 47 (3): 519-28.
17. Nishiyama KK, Macdonald HM, Buie HR, Hanley DA, Boyd SK., Postmenopausal women with osteopenia have higher cortical porosity and thinner cortices at the distal radius and tibia than women with normal aBMD: an in vivo HR-pQCT study. J Bone Miner Res. 2010 Apr; 25 (4): 882-90.
18. Laib A, Hauselmann HJ, Ruegsegger P., In vivo high resolution 3D-QCT of the human forearm. Technol Health Care. 1998 Dec; 6 (5-6): 329-37.
19. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF., Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res. 2003; Nov; 18 (11): 1932-41.
20. Eriksen EF, Melsen F, Sod E, Barton I, Chines A., Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone. 2002 Nov; 31 (5): 620-5.
21. Hirano T, Burr DB, Cain RL, Hock JM., Changes in geometry and cortical porosity in adult, ovary-intact rabbits after 5 months treatment with LY333334 (hPTH 1-34). Calcif Tissue Int. 2000 Jun; 66 (6): 456-60.
22. Lindsay R, Zhou H, Cosman F, Nieves J, Dempster DW, Hodsman AB., Effects of a one-month treatment with PTH(1-34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J Bone Miner Res. 2007 Apr; 22 (4): 495-502.
23. Zanchetta JR, Bogado CE, Ferretti JL, Wang O, Wilson MG, Sato M, Gaich GA, Dalsky GP, Myers SL., Effects of teriparatide [recombinant human parathyroid hormone (1-34)] on cortical bone in postmenopausal women with osteoporosis. J Bone Miner Res. 2003 Mar; 18 (3): 539-43.
24. Miller MA, Bare SP, Recker RR, Smith SY, Fox J., Intratrabecular tunneling increases trabecular number throughout the skeleton of ovariectomized rhesus monkeys treated with parathyroid hormone 1-84. Bone. 2008 Jun; 42 (6): 1175-83.
25. Jobke B, Muche B, Burghardt AJ, Semler J, Link TM, Majumdar S., Teriparatide in bisphosphonate-resistant osteoporosis: microarchitectural changes and clinical results after 6 and 18 months. Calcif Tissue Int. 2011 Aug; 89 (2): 130-9.
26. Seeman E, Delmas P.D, Hanley D.A, Sellmeyer D, Cheung A.M, Shane E, Kearns A, Thomas T, Boyd S.K, Boutroy S, Bogado C, Majumdar S, Fan M, Libanati C, Zanchetta J., Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res. 2010; Aug; 25 (8): 1886-94.
27. Burghardt AJ, Kazakia GJ, Sode M, de Papp AE, Link TM, Majumdar S., A longitudinal HR-pQCT study of alendronate treatment in postmenopausal women with low bone density: relations among density, cortical and trabecular microarchitecture, biomechanics, and bone turnover. J Bone Miner Res. 2010 Dec; 25 (12): 2282-95.
28. Chapurlat RD, Laroche M, Thomas T, Rouanet S, Delmas PD, De Vernejoul MC., Effect of oral monthly ibandronate on bone microarchitecture in women with osteopenia-a randomized placebo-controlled trial. Osteoporos Int. 2012 Mar 9. [Epub ahead of print].
29. Rizzoli R, Chapurlat RD, Laroche JM, Krieg MA, Thomas T, Frieling I, Boutroy S, Laib A, Bock O, Felsenberg D., Effects of strontium ranelate and alendronate on bone microstructure in women with osteoporosis. Results of a 2-year study. Osteoporos Int. 2012 Jan; 23 (1): 305-15.
30. Eastell R, Walsh JS, Watts NB, Siris E., Bisphosphonates for postmenopausal osteoporosis. Bone. 2011 Jul; 49 (1): 82-8.
31. Macdonald HM, Nishiyama KK, Kang J, Hanley DA, Boyd SK., Age-related patterns of trabecular and cortical bone loss differ between sexes and skeletal sites: a population-based HR-pQCT study. J Bone Miner Res. 2011 Jan; 26 (1): 50-62.
32. Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ., Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone. 2000 Nov; 27 (5): 687-94.
33. Keaveny TM, McClung MR, Wan X, Kopperdahl DL, Mitlak BH, Krohn K., Femoral strength in osteoporotic women treated with teriparatide or alendronate. Bone. 2012 Jan; 50 (1): 165-70.
34. Keaveny TM, Hoffmann PF, Singh M, Palermo L, Bilezikian JP, Greenspan SL, Black DM., Femoral bone strength and its relation to cortical and trabecular changes after treatment with PTH, alendronate, and their combination as assessed by finite element analysis of quantitative CT scans. J Bone Miner Res. 2008 Dec; 23 (12): 1974-82.
35. Burghardt AJ, Kazakia GJ, Ramachandran S, Link TM, Majumdar S., Age- and gender-related differences in the geometric properties and biomechanical significance of intracortical porosity in the distal radius and tibia. J Bone Miner Res. 2010 May; 25 (5): 983-93.
36. European Medicines Agency. Forteo. Available at: www.emea.europa.eu. Accessed 2012 May 3.
37. European Medicines Agency. Preotact. Available at: www.emea.europa.eu. Accessed 2012 May 3.
38. Divieti P, Inomata N, Chapin K, Singh R, Juppner H, Bringhurst FR., Receptors for the carboxyl-terminal region of pth(1-84) are highly expressed in osteocytic cells. Endocrinology. 2001 Feb; 142 (2): 916-25.
39. Sutherland MK, Rao LG, Wylie JN, Gupta A, Ly H, Sodek J, Murray TM., Carboxyl-terminal parathyroid hormone peptide (53-84) elevates alkaline phosphatase and osteocalcin mRNA levels in SaOS-2 cells. J Bone Miner Res. 1994 Apr; 9 (4): 453-8.
40. Obermayer-Pietsch BM, Marin F, McCloskey EV, Hadji P, Farrerons J, Boonen S, Audran M, Barker C, Anastasilakis AD, Fraser WD, Nickelsen T., Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. J Bone Miner Res. 2008; Oct; 23 (10): 1591-600.
41. Graeff C, Timm W, Nickelsen TN, Farrerons J, Marin F, Barker C, Gluer CC., Monitoring teriparatide-associated changes in vertebral microstructure by high-resolution CT in vivo: results from the EUROFORS study. J Bone Miner Res. 2007 Sep; 22 (9): 1426-33.